NASDAQ: CJJDChina Jo Jo Drugstores Inc Stock
$2.86-0.07 (-2.39%)
Updated Apr 24, 2024
CJJD Price
$2.86
Fair Value Price
N/A
Market Cap
$4.81M
52 Week Low
$2.39
52 Week High
$24.60
P/E
-0.07x
P/B
0.25x
P/S
0.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$154.66M
Earnings
-$21.47M
Gross Margin
21.5%
Operating Margin
-13.88%
Profit Margin
-13.9%
Debt to Equity
4.09
Operating Cash Flow
-$4M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CJJD Overview
China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2021, it had 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.
Zen Score
–
Industry Average (19)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CJJD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CJJD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CJJD is good value based on its book value relative to its share price (0.25x), compared to the US Pharmaceutical Retailers industry average (1.15x)
P/B vs Industry Valuation
CJJD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CJJD due diligence checks available for Premium users.
Be the first to know about important CJJD news, forecast changes, insider trades & much more!
CJJD News
Valuation
CJJD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-2.7x
Market
41.27x
CJJD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.25x
Industry
1.15x
CJJD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CJJD's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CJJD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CJJD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$94.8M
Liabilities
$77.2M
Debt to equity
4.09
CJJD's short-term assets ($69.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CJJD's short-term assets ($69.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CJJD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CJJD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CJJD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CJJD vs Pharmaceutical Retailer Stocks
China Jo Jo Drugstores Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.